---
title: "Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed Pharmaceuticals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305072970.md"
description: "Mentari Therapeutics published pro forma combined financial statements with InMed Pharmaceuticals following their merger closed on November 6, 2026. As of June 30, 2026, cash totaled $478.12 million, supported by $490 million in pre-closing financing. Total assets were $478.78 million against liabilities of $11.42 million. The company reported a net loss of $37.29 million for the first half of 2026 and $26.9 million for all of 2025."
datetime: "2026-11-10T21:56:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305072970.md)
  - [en](https://longbridge.com/en/news/305072970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305072970.md)
generator: "portal-rs"
---

# Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed Pharmaceuticals

-   Mentari Therapeutics published pro forma financial statements reflecting its merger with InMed Pharmaceuticals, which closed November 6, 2026. \* Cash totaled $478.12 million as of June 30, 2026, reflecting $490 million in pre-closing financing, including convertible notes. \* Total assets reached $478.78 million, against liabilities of $11.42 million. \* Net loss from continuing operations totaled $37.29 million for the six months ended June 30, 2026; research spending reached $31.1 million. \* For 2025, net loss from continuing operations was $26.9 million, with operating expenses of $27.54 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-455640), on November 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INM.US](https://longbridge.com/en/quote/INM.US.md)
- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [ADAR1 Capital Management reports acquisition of $34,571.592 in Mentari Therapeutics common shares](https://longbridge.com/en/news/304932745.md)
- [Mentari Therapeutics Names Todd Shegog to Board, Audit Committee Chair](https://longbridge.com/en/news/304857107.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**